Your browser doesn't support javascript.
loading
A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies.
Lin, C-C; Su, W-C; Yen, C-J; Hsu, C-H; Su, W-P; Yeh, K-H; Lu, Y-S; Cheng, A-L; Huang, D C-L; Fritsch, H; Voss, F; Taube, T; Yang, J C-H.
Afiliação
  • Lin CC; Department of Oncology, National Taiwan University Hospital, 7 Chung Shan S Road, Taipei 100, Taiwan.
  • Su WC; Department of Internal Medicine, National Cheng Kung University, Medical College and Hospital, 138 Sheng-Li Road, Tainan 704, Taiwan.
  • Yen CJ; Department of Internal Medicine, National Cheng Kung University, Medical College and Hospital, 138 Sheng-Li Road, Tainan 704, Taiwan.
  • Hsu CH; 1] Department of Oncology, National Taiwan University Hospital, 7 Chung Shan S Road, Taipei 100, Taiwan [2] Graduate Institute of Oncology and Cancer Research Centre, National Taiwan University College of Medicine, 2 Xuzhou Road, Taipei 100, Taiwan.
  • Su WP; Department of Internal Medicine, National Cheng Kung University, Medical College and Hospital, 138 Sheng-Li Road, Tainan 704, Taiwan.
  • Yeh KH; 1] Department of Oncology, National Taiwan University Hospital, 7 Chung Shan S Road, Taipei 100, Taiwan [2] Graduate Institute of Oncology and Cancer Research Centre, National Taiwan University College of Medicine, 2 Xuzhou Road, Taipei 100, Taiwan.
  • Lu YS; Department of Oncology, National Taiwan University Hospital, 7 Chung Shan S Road, Taipei 100, Taiwan.
  • Cheng AL; 1] Department of Oncology, National Taiwan University Hospital, 7 Chung Shan S Road, Taipei 100, Taiwan [2] Graduate Institute of Oncology and Cancer Research Centre, National Taiwan University College of Medicine, 2 Xuzhou Road, Taipei 100, Taiwan.
  • Huang DC; Boehringer Ingelheim Taiwan Limited, 12F, 49/51 Min Sheng East Road, Taipei 100, Taiwan.
  • Fritsch H; Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, 88397 Biberach, Germany.
  • Voss F; Boehringer Ingelheim Pharma GmbH & Co. KG., Binger Strasse 173, Ingelheim, Germany 55216.
  • Taube T; Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, 88397 Biberach, Germany.
  • Yang JC; 1] Department of Oncology, National Taiwan University Hospital, 7 Chung Shan S Road, Taipei 100, Taiwan [2] Graduate Institute of Oncology and Cancer Research Centre, National Taiwan University College of Medicine, 2 Xuzhou Road, Taipei 100, Taiwan.
Br J Cancer ; 110(10): 2434-40, 2014 May 13.
Article em En | MEDLINE | ID: mdl-24755882
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pteridinas / Proteínas Proto-Oncogênicas / Terapia de Salvação / Proteínas Serina-Treonina Quinases / Proteínas de Ciclo Celular / Inibidores de Proteínas Quinases / Proteínas de Neoplasias / Neoplasias / Antineoplásicos Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Revista: Br J Cancer Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Taiwan
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pteridinas / Proteínas Proto-Oncogênicas / Terapia de Salvação / Proteínas Serina-Treonina Quinases / Proteínas de Ciclo Celular / Inibidores de Proteínas Quinases / Proteínas de Neoplasias / Neoplasias / Antineoplásicos Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Revista: Br J Cancer Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Taiwan